China's Simcere Pharmaceutical Becomes Beacon For Disclosing GMP Problems At New Vaccine Subsidiary

BEIJING - Just weeks after acquiring a controlling equity stake in vaccine developer Jiangsu Yanshen, leading Chinese drug maker Simcere Pharmaceutical is pressing its new subsidiary to freeze production and replace two top executives that may have been responsible for lapses in good manufacturing practice standards at the vaccine facility